HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BRL 35135
structure given in first source
Also Known As:
BRL 35135, hydrombromide, (R*,R*)-(+-)-isomer; BRL-35135; BRL35135A; methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate
Networked:
7
relevant articles (
1
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amines: 4871
Ethylamines: 5
Phenethylamines: 28
BRL 35135: 7
Experts
1.
Larson, Christopher J
: 1 article (01/2019)
Related Diseases
1.
Insulin Resistance
11/22/1996 - "
These findings suggest that the improvement of metabolic disorders by BRL35135A may be due to improvement in insulin resistance as well as reduction of visceral fat weight.
"
01/01/1992 - "
In 10-d studies in obese and diabetic patients, BRL 35135 produced improvements in glucose tolerance and insulin sensitivity.
"
01/01/1989 - "
BRL 35135 is a novel oral agent which, when dosed chronically to obese rodents with abnormal glucose tolerance, improves both insulin sensitivity and glucose tolerance.
"
01/01/1989 - "
The results suggest that BRL 35135 improves glucose tolerance by an increase in insulin sensitivity that is independent of body weight.
"
01/01/1989 - "
Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects.
"
2.
Body Weight (Weight, Body)
11/22/1996 - "
In fa/fa rats, daily administration of BRL35135A (0.05 mg/kg/day)) for 6 weeks reduced the visceral white fat weight/total energy intake ratio, particularly for mesenteric fat, without any clear effect on body weight gain.
"
01/01/1989 - "
No significant changes in body weight occurred during the 10-day treatment with BRL 35135.
"
11/22/1996 - "
In db/db mice, four weeks of oral administration of BRL35135A (0.5 and 5 mg/kg/day) decreased body weight gain and reduced white fat weight.
"
01/01/1989 - "
The results suggest that BRL 35135 improves glucose tolerance by an increase in insulin sensitivity that is independent of body weight.
"
11/22/1996 - "
In fa/fa rats, BRL35135A (0.005 mg/kg/day) was also effective in improving hyperinsulinemia, glucose intolerance, and hypertriglyceridemia without any effect on body weight gain or fat distribution.
"
3.
Glucose Intolerance
11/22/1996 - "
In fa/fa rats, BRL35135A (0.005 mg/kg/day) was also effective in improving hyperinsulinemia, glucose intolerance, and hypertriglyceridemia without any effect on body weight gain or fat distribution.
"
4.
Hypertriglyceridemia
11/22/1996 - "
In fa/fa rats, BRL35135A (0.005 mg/kg/day) was also effective in improving hyperinsulinemia, glucose intolerance, and hypertriglyceridemia without any effect on body weight gain or fat distribution.
"
5.
Hyperlipidemias (Hyperlipidemia)
11/22/1996 - "
Moreover, BRL35135A at 0.05 mg/kg/day elevated serum insulin levels and improved hyperglycemia in db/db mice without reducing body weight gain, whereas at doses of 0.5 and 5 mg/kg/day it ameliorated hyperglycemia and hyperlipidemia, and tended to decrease serum insulin levels.
"
Related Drugs and Biologics
1.
Insulin (Novolin)
2.
Glucose (Dextrose)
3.
disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylate
4.
BRL 26830A
5.
Adrenergic Receptors (Adrenergic Receptor)
6.
Neuropeptide Y
7.
atipamezole
Related Therapies and Procedures
1.
Therapeutics
2.
Oral Administration